Firebrick Pharma

Firebrick Pharma is an Australian pharmaceutical innovator with a breakthrough product. We encourage users of our Twitter page to read our social media policy.

[Firebrick Pharma @FirebrickPharma]

We're pleased to share that our patent titled "Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes" has been accepted in Canada: https://t.co/TwvIKG3mRl

[Firebrick Pharma @FirebrickPharma]

Firebrick's Executive Chairman Dr Peter Molloy joined ASX Briefs with Andrew Musgrave to discuss the company’s shift from R&D to commercial execution and why the recent approval of Nasodine in Indonesia changes the scale of the Company's opportunity: https://t.co/rC52RTAW1b

[Firebrick Pharma @FirebrickPharma]

For those that missed yesterday's investor webinar from Executive Chair Dr Peter Molloy, a replay is now available at: https://t.co/yQ4P3NNVKy

[Firebrick Pharma @FirebrickPharma]

Executive Chair Dr Peter Molloy is hosting an investor update webinar on Monday 27 April at 11am AEST , following recent news including the approval of Nasodine Nasal Spray in Indonesia and the $1.5m Placement.

To register, please visit: https://t.co/zpQFPWiUqB

[Firebrick Pharma @FirebrickPharma]

We're pleased to share that we have been featured in a recent edition of Biotech Daily by prominent small-cap share analyst and business journalist Tim Boreham, where he discussed the ongoing global rollout of Nasodine and the Company's future outlook: https://t.co/z1LtrOWh2h

[Firebrick Pharma @FirebrickPharma]

Executive Chair Dr Peter Molloy is hosting an investor update webinar on Monday 27 April at 11am AEST , following recent news including the approval of Nasodine Nasal Spray in Indonesia and the $1.5m Placement.

To register, please visit: https://t.co/zpQFPWiUqB

[Firebrick Pharma @FirebrickPharma]

Firebrick is pleased to share that it has secured firm commitments from investors for approximately $1.5 million: https://t.co/Tmeg8qgivF

The Placement was strongly supported by new and existing sophisticated investors.

[Firebrick Pharma @FirebrickPharma]

We're pleased to announce that Nasodine has been approved by the Indonesian Government as an ‘antiseptic’ product within the ‘Household Health Supplies’ category: https://t.co/wm2CZ8VAu3

The approval allows importation & marketing of Nasodine in Indonesia, effective immediately.

[Firebrick Pharma @FirebrickPharma]

The presentation also outlines our expectation to introduce two new Nasodine® products to the range, and to achieve approval or allowed sales of at least one Nasodine® product in up to 10 countries over the next three years.

[Firebrick Pharma @FirebrickPharma]

We are pleased to release an investor update presentation, highlighting strong Nasodine® portfolio sales growth in both the U.S. and Singapore: https://t.co/bd1BVZHROh

[Firebrick Pharma @FirebrickPharma]

Big news for ASX:FRE! 🚀 Firebrick Pharma has officially launched Nasodine® Throat Spray in Singapore! 🇸🇬🔹 Dual "nasal & oral" defense against cold germs🔹 Perfect for travel & commuting ✈️ 🔹 Rolling out to Singapore hospitals & HCPs now!#ASX #Biotech #Singapore

[Firebrick Pharma @FirebrickPharma]

Firebrick Pharma (ASX:FRE) is excited to confirm we've commenced manufacturing of our new Nasodine® Throat Spray! 🎉Set for export in November 2025, this marks a significant expansion of our Nasodine brand. Learn more here: https://t.co/oF1IEwBPQ4
#ASX #BioTech #ASXnews

[Firebrick Pharma @FirebrickPharma]

WATCH: Important new plans for Firebrick! 🚀 Our Executive Chairman, Peter Molloy, recently joined @HotCopper 's "The Market Link" to discuss our latest announcement & renewed focus on the US market. This is a must-watch

https://t.co/6kVcRW7ByG

#commoncold #cold #nasodine #ASX

[Firebrick Pharma @FirebrickPharma]

BIG NEWS FOR NASODINE

Newly published Phase 3 clinical trial data on Nasodine® Nasal Spray concludes: “Nasodine is an effective and clinically meaningful treatment for the common cold.”

Learn more about Nasodine: https://t.co/jr7uXrBvNd

#commoncold #cold #treatment #nasodine

[Firebrick Pharma @FirebrickPharma]

We are thrilled to announce the launch of Nasodine in Fiji and the South Pacific! 🤝 The exclusive agreement is with Makans Ltd, the largest pharmaceutical wholesaler in the region! ✅ #ASX #pharma #Fiji #SouthPacific #nasalspray

[Firebrick Pharma @FirebrickPharma]

We're excited to launch a healthcare professional campaign with Innorini Life Sciences in Singapore from 1 November! 🤝 Innorini’s medical reps will promote and sell Nasodine to GPs and hospitals, with a focus on the top 400 dispensing GPs in the first few months. #ASX #news

[Firebrick Pharma @FirebrickPharma]

📹 WATCH: Executive Chairman Peter Molloy yesterday presented a webinar outlining the new Firebrick strategy. If you missed this presentation, you can click the link to watch it here. https://t.co/s60XMvUEa7
#ASX #pharma #Nasodine #investing

[Firebrick Pharma @FirebrickPharma]

Big news! 🔥 Former head of J&J Consumer Health in APAC, Keith Shortall, will drive distribution and partnering of Nasodine in Asia and we have filed Nasodine as a nasal antiseptic in Europe! 💪

#nasalspray #ASX #news

[Firebrick Pharma @FirebrickPharma]

We're excited to share Dr Peter Molloy's interview with @asxongrafa where he outlined the company’s business model for Nasodine which is available in the US and Singapore, and will soon be launched in the Philippines.

Watch: https://t.co/G9qYH3DfPG

#asx #nasalspray #pharma

[Firebrick Pharma @FirebrickPharma]

We are very excited to announce an agreement which will allow Nasodine® Nasal Spray to be launched as an OTC into the Philippines without any additional clinical studies!! 🔥

Read more https://t.co/3ESeCCbwOi

#nasodine #philippines #nasalspray #ASX #news #pharmaceuticalnews

[Firebrick Pharma @FirebrickPharma]

Nasodine has been featured on ASX Briefs!🎙️The interview provided an opportunity to discuss our plans for Nasodine in the US and Singapore. Listen to the full episode here.

https://t.co/LsfIkramkm

#nasodine #asx #nasalspray #pharma